We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Family History Misses Actionable Germline Variants in Many Ovarian Cancer Patients Over 70

MedXY Editorial Team•Aug 18, 2026•news
germline testingovarian cancerfamily historyBRCA

Highlight

In more than 113,000 ovarian cancer patients undergoing germline testing, 6.6% of those aged 70 years or older carried pathogenic or likely pathogenic variants in established ovarian cancer susceptibility genes.

Older patients were about 1.5-fold less likely to report a family history of cancer, suggesting that family-history-based referral strategies lose sensitivity with age.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Reevaluating Colorectal Cancer Surveillance in Inflammatory Bowel Disease: The Role of Family History Beyond Early-Onset CasesA nationwide cohort study reveals that in IBD patients, colorectal cancer risk increases notably with multiple affected relatives, challenging current guidelines prioritizing early-onset family history for surveillance.Sep 6, 2026Harnessing Artificial Intelligence for Early Detection of Ovarian Cancer: Development and Validation of a Predictive Risk ModelA novel AI-driven risk prediction model for ovarian cancer demonstrates high accuracy and potential to improve early detection in screening settings.Aug 31, 2026Oral Anticoagulation Significantly Lowers Venous Thromboembolism Rates in Ovarian Cancer Patients on First-Line Chemotherapy: Insights from a Quality Improvement ProjectA quality improvement initiative integrating oral anticoagulants reduced venous thromboembolism incidence in ovarian cancer patients undergoing first-line chemotherapy without increasing bleeding risks.Aug 25, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Trends in Incidence, Mortality, and Survival of Endometrial, Ovarian, and Cervical Cancers in Young Nordic Women: Insights from 40 Years of Registry Data
This article analyzes 40-year trends in incidence, mortality, and survival of endometrial, ovarian, and cervical cancers among Nordic women aged 0-49, highlighting evolving epidemiology and implications for age-specific prevention.
Aug 22, 2026
Niraparib Versus Platinum-Taxane Chemotherapy as Neoadjuvant Treatment in Advanced HR-Deficient Ovarian Cancer: Insights from the OPAL Phase 2 TrialThe OPAL phase 2 trial compared neoadjuvant niraparib to standard platinum-taxane chemotherapy in newly diagnosed HR-deficient advanced ovarian cancer, showing inferior response rates with niraparib and a safety profile consistent with PARPAug 21, 2026
Evaluating CT-Based Models to Predict Residual Disease and Surgical Extent in Interval Debulking Surgery for Ovarian CancerThis study assesses the predictive accuracy of the MSKCC CT-based model for residual disease after neoadjuvant chemotherapy in advanced ovarian cancer, showing limited discrimination that improves with optimized clinical parameters. CT findAug 19, 2026